Actinium Pharmaceuticals Announced Data Was Presented At Society Of Immunotherapy Of Cancer Annual Meeting, For Actimab-A, Targeted Radiotherapeutic Comprised Of The CD33 Targeting Antibody Lintuzumab And The Actinium-225 Alpha-particle Emitting Payload
Portfolio Pulse from Benzinga Newsdesk
Actinium Pharmaceuticals has presented data at the Society of Immunotherapy of Cancer Annual Meeting for Actimab-A, a targeted radiotherapeutic comprised of the CD33 targeting antibody Lintuzumab and the Actinium-225 alpha-particle emitting payload.
November 06, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Actinium Pharmaceuticals' presentation of data for Actimab-A at a major conference could potentially boost investor confidence in the company's product pipeline.
The presentation of data at a major conference is often a positive signal for a pharmaceutical company, as it indicates progress in the development of its products. This could potentially lead to increased investor confidence in Actinium Pharmaceuticals, which could in turn have a positive impact on its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100